Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?

References

• Caputi FF, Nicora M, Simeone R, et al. Tapentadol: an analgesic that differs from classic opioids due to its noradrenergic mechanism of action. Minerva Med. 2019;110(1):62–78.
   PubMed Web of Science ®Google Scholar
• Raffa RB, Elling C, Tzschentke TM. Does 'Strong analgesic' equal 'strong opioid'? Tapentadol and the concept of 'µ-Load'. Adv Ther. 2018;35(10):1471–1484.
   PubMed Web of Science ®Google Scholar
• Dickenson AH, Kress HG. Tapentadol: a new option for the treatment of cancer and noncancer pains. JPR. 2019;12:1509–1511.
   Google Scholar
• Morlion B, Coluzzi F, Aldington D, et al. Pain chronification: what should a non-pain medicine specialist know? Curr Med Res Opin. 2018;34(7):1169–1178.
   PubMed Web of Science ®Google Scholar
• McCarberg B, Peppin J. Pain Pathways and nervous system plasticity: learning and memory in pain. Pain Med. 2019;20(12):2421–2437.
   PubMed Web of Science ®Google Scholar
• Bourne S, Machado AG, Nagel SJ. Basic anatomy and physiology of pain pathways. Neurosurg Clin N Am. 2014;25(4):629–638.
   PubMed Web of Science ®Google Scholar
• Kuner R. Central mechanisms of pathological pain. Nat Med. 2010;16(11):1258–1266.
   PubMed Web of Science ®Google Scholar
• Ossipov MH, Morimura K, Porreca F. Descending pain modulation and chronification of pain. Curr Opin Support Palliat Care. 2014;8(2):143–151.
   PubMed Web of Science ®Google Scholar
• Romualdi P, Grilli M, Canonico PL, et al. Pharmacological rationale for tapentadol therapy: a review of new evidence. JPR. 2019;12:1513–1520.
   Google Scholar
• Bannister K, Dickenson AH. What the brain tells the spinal cord. Pain. 2016;157(10):2148–2151.
   PubMed Web of Science ®Google Scholar
• Bannister K, Dickenson AH. The plasticity of descending controls in pain: translational probing. J Physiol. 2017;595(13):4159–4166.
   PubMed Web of Science ®Google Scholar
• Tiwari V, Guan Y, Raja SN. Modulating the delicate glial-neuronal interactions in neuropathic pain: promises and potential caveats. NeurosciBiobehav Rev. 2014;45:19–27.
   PubMed Web of Science ®Google Scholar
• Caraci F, Merlo S, Drago F, et al. Rescue of noradrenergic system as a novel pharmacological strategy in the treatment of chronic pain: focus on microglia activation. Front Pharmacol. 2019;10:1024.
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Fornasari D, Pergolizzi J, et al. From acute to chronic pain: tapentadol in the progressive stages of this disease entity. Eur Rev Med Pharmacol Sci. 2017;21(7):1672–1683.
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Polati E, Freo U, et al. Tapentadol: an effective option for the treatment of back pain. JPR. 2019;12:1521–1528.
   Google Scholar
• Anand P, Dickenson A, Finco G, et al. Novel insights on the management of pain: highlights from the 'Science of Relief' meeting. Pain Manag. 2019;9(6):521–533.
   PubMed Web of Science ®Google Scholar
• Thakur M, Dickenson AH, Baron R. Osteoarthritis pain: nociceptive or neuropathic? Nat Rev Rheumatol. 2014;10(6):374–380.
   PubMed Web of Science ®Google Scholar
• Jimenez-Andrade JM, Mantyh PW. Sensory and sympathetic nerve fibers undergo sprouting and neuroma formation in the painful arthritic joint of geriatric mice. Arthritis Res Ther. 2012;14(3):R101.
   PubMed Web of Science ®Google Scholar
• Ghilardi JR, Freeman KT, Jimenez-Andrade JM, et al. Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. Arthritis Rheum. 2012;64(7):2223–2232.
   PubMed Web of Science ®Google Scholar
• Lockwood SM, Bannister K, Dickenson AH. An investigation into the noradrenergic and serotonergic contributions of diffuse noxious inhibitory controls in a monoiodoacetate model of osteoarthritis. J Neurophysiol. 2019;121(1):96–104.
   PubMed Web of Science ®Google Scholar
• Lluch E, Torres R, Nijs J, et al. Evidence for central sensitization in patients with osteoarthritis pain: a systematic literature review. EJP. 2014;18(10):1367–1375.
   PubMed Web of Science ®Google Scholar
• Dimitroulas T, Duarte RV, Behura A, et al. Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment. Semin Arthritis Rheum. 2014;44(2):145–154.
   PubMed Web of Science ®Google Scholar
• Fingleton C, Smart K, Moloney N, et al. Pain sensitization in people with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2015;23(7):1043–1056.
   PubMed Web of Science ®Google Scholar
• LluchGirbés E, Dueñas L, Barbero M, et al. Expanded distribution of pain as a sign of central sensitization in individuals with symptomatic knee osteoarthritis. Phys Ther. 2016;96:1196–1207.
   PubMed Web of Science ®Google Scholar
• Steen Pettersen P, Neogi T, Magnusson K, et al. Peripheral and central sensitization of pain in individuals with hand osteoarthritis and associations with self-reported pain severity. Arthritis Rheumatol. 2019;71(7):1070–1077.
   PubMed Web of Science ®Google Scholar
• Carlesso LC, Segal NA, Frey-Law L, et al. Pain susceptibility phenotypes in those free of knee pain with or at risk of knee osteoarthritis: the multicenter osteoarthritis study. Arthritis Rheumatol. 2019;71(4):542–554.
   PubMed Web of Science ®Google Scholar
• Soni A, Wanigasekera V, Mezue M, et al. Central sensitization in knee osteoarthritis: relating presurgical brainstem neuroimaging and PainDETECT-based patient stratification to arthroplasty outcome. Arthritis Rheumatol. 2019;71(4):550–560.
   PubMed Web of Science ®Google Scholar
• Belluzzi E, Stocco E, Pozzuoli A, et al. Contribution of infrapatellar fat pad and synovial membrane to knee osteoarthritis pain. Biomed Res Int. 2019;2019:1.
   Web of Science ®Google Scholar
• Apkarian AV, Sosa Y, Sonty S, et al. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci. 2004;24(46):10410–10415.
   PubMed Web of Science ®Google Scholar
• Fritz HC, McAuley JH, Wittfeld K, et al. Chronic back pain is associated with decreased prefrontal and anterior insular gray matter: results from a population-based cohort study. J Pain. 2016;17(1):111–118.
   PubMed Web of Science ®Google Scholar
• Seminowicz DA, Wideman TH, Naso L, et al. Effective treatment of chronic low back pain in humans reverses abnormal brain anatomy and function. J Neurosci. 2011;31(20):7540–7550.
   PubMed Web of Science ®Google Scholar
• Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018;22(2):216–241.
   PubMed Web of Science ®Google Scholar
• Cohen E, Lee YC. A mechanism-based approach to the management of osteoarthritis pain. Curr Osteoporos Rep. 2015;13:399–406.
   PubMed Web of Science ®Google Scholar
• Rojo ML, Rodríguez-Gaztelumendi A, Pazos Á, et al. Differential adaptive changes on serotonin and noradrenaline transporters in a rat model of peripheral neuropathic pain. NeurosciLett. 2012;515:181–186.
   PubMed Web of Science ®Google Scholar
• Pertovaara A. The noradrenergic pain regulation system: a potential target for pain therapy. Eur J Pharmacol. 2013;716(1–3):2–7.
   PubMed Web of Science ®Google Scholar
• Uchida H, Ma L, Ueda H. Epigenetic gene silencing underlies C-fiber dysfunctions in neuropathic pain. J Neurosci. 2010;30(13):4806–4814.
   PubMed Web of Science ®Google Scholar
• Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain. 2010;14(8):781–783.
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kögel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs. 2014;28(4):319–329.]
   PubMed Web of Science ®Google Scholar
• Meske DS, Xie JY, Oyarzo J, et al. Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain. Neurosci Lett. 2014;562:91–96.
   PubMed Web of Science ®Google Scholar
• Bee LA, Bannister K, Rahman W, et al. Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain. 2011;152(1):131–139.
   PubMed Web of Science ®Google Scholar
• Torres-Sanchez S, Alba-Delgado C, Llorca-Torralba M, et al. Effect of tapentadol on neurons in the locus coeruleus. Neuropharmacology. 2013;72:250–258.
   PubMed Web of Science ®Google Scholar
• Falk S, Patel R, Heegaard A, et al. Spinal neuronal correlates of tapentadol analgesia in cancer pain: a back-translational approach. EJP. 2015;19(2):152–158.
   PubMed Web of Science ®Google Scholar
• Franchi S, Amodeo G, Gandolla M, et al. Effect of tapentadol on splenic cytokine production in mice. AnesthAnalg. 2017;124(3):986–995.
   Google Scholar
• Lockwood SM, Dickenson AH. A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain. Eur J Pain. 2019;23(6):1185–1195.
   PubMed Web of Science ®Google Scholar
• Patel R, Dickenson AH. Modality selective roles of pro-nociceptive spinal 5-HT2A and 5-HT3 receptors in normal and neuropathic states. Neuropharmacology. 2018;143:29–37.
   PubMed Web of Science ®Google Scholar
• Baron R, Kern U, Müller M, et al. Effectiveness and tolerability of a moderate dose of tapentadol prolonged release for managing severe, chronic low back pain with a neuropathic component: an open-label continuation arm of a randomized phase 3b study. Pain Pract. 2015;15(5):471–486.
   PubMed Web of Science ®Google Scholar
• Niesters M, Proto PL, Aarts L, et al. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J Anaesth. 2014;113(1):148–156.
   PubMed Web of Science ®Google Scholar
• Polati E, Canonico PL, Schweiger V, et al. Tapentadol: an overview of the safety profile. JPR. 2019;12:1569–1576.
   Google Scholar
• Stollenwerk A, Sohns M, Heisig F, et al. Review of post-marketing safety data on tapentadol, a centrally acting analgesic. Adv Ther. 2018;35(1):12–30.
   PubMed Web of Science ®Google Scholar
• Els C, Jackson TD, Hagtvedt R, et al. High-dose opioids for chronic non-cancer pain: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017;10:CD012299.
   PubMed Web of Science ®Google Scholar
• Thakur D, Dickerson S, Kumar Bhutani M, et al. Impact of prolonged-release oxycodone/naloxone on outcomes affecting patients' daily functioning in comparison with extended-release tapentadol: a systematic review. Clin Ther. 2015;37(1):212–224.
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV, Jr, LeQuang JA, Taylor R, Jr, et al. Designing safer analgesics: a focus on μ-opioid receptor pathways. Expert Opin Drug Discov. 2018;13(10):965–972.
   PubMed Web of Science ®Google Scholar
• Dart RC, Cicero TJ, Surratt HL, et al. Assessment of the abuse of tapentadol immediate release: the first 24 months. J Opioid Manag. 2012;8(6):395–402.
   PubMedGoogle Scholar
• Butler SF, McNaughton EC, Black RA. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. Pain Med. 2015;16(1):119–130.
   PubMed Web of Science ®Google Scholar
• Rinonapoli G, Coaccioli S, Panella L. Tapentadol in the treatment of osteoarthritis: pharmacological rationale and clinical evidence. JPR. 2019;12:1529–1536.
   Google Scholar
• Kress HG, Coluzzi F. Tapentadol in the management of cancer pain: current evidence and future perspectives. JPR. 2019;12:1553–1560.
   Google Scholar
• Freo U, Romualdi P, Kress HG. Tapentadol for neuropathic pain: a review of clinical studies. JPR. 2019;12:1537–1551.
   Google Scholar
• Panella L, Rinonapoli G, Coaccioli S. Where should analgesia lead to? Quality of life and functional recovery with tapentadol. JPR. 2019;12:1561–1567.
   Google Scholar
• Dell'Isola A, Steultjens M. Classification of patients with knee osteoarthritis in clinical phenotypes: Data from the osteoarthritis initiative. PLOS One. 2018;13(1):e0191045.
   PubMed Web of Science ®Google Scholar
• Langford RM, Knaggs R, Farquhar-Smith P, et al. Is tapentadol different from classical opioids? A review of the evidence. Br J Pain. 2016;10(4):217–221.
   PubMed Web of Science ®Google Scholar
• Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig. 2010;30(8):489–505.
   PubMed Web of Science ®Google Scholar
• Steigerwald I, Schenk M, Lahne U, et al. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. Clin Drug Investig. 2013;33(9):607–619.
   PubMed Web of Science ®Google Scholar
• Banerjee M, Mondal S, Sarkar R, et al. Comparative study of efficacy and safety of tapentadol versus etoricoxib in mild to moderate grades of chronic osteorthritis of knee. Indian J Rheumatol. 2016;11(1):21–25.
   Google Scholar
• Serrie A, Lange B, Steup A. Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study. Curr Med Res Opin. 2017;33(8):1423–1432.
   PubMed Web of Science ®Google Scholar
• Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother. 2010;11(11):1787–1804.
   PubMed Web of Science ®Google Scholar
• Gálvez R, Schäfer M, Hans G, et al. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. Adv Therapy. 2013;30(3):229–259.
   PubMed Web of Science ®Google Scholar
• Baron R, Martin-Mola E, Müller M, et al. Effectiveness and safety of tapentadol prolonged release (PR) versus a combination of tapentadol PR and pregabalin for the management of severe, chronic low back pain with a neuropathic component: a randomized, double-blind, phase 3b study. Pain Pract. 2015;15(5):455–470.
   PubMed Web of Science ®Google Scholar
• Baron R, Likar R, Martin-Mola E, et al. Effectiveness of tapentadol prolonged release (PR) compared with oxycodone/naloxone pr for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 study. Pain Pract. 2016;16(5):580–599.
   PubMed Web of Science ®Google Scholar
• Santos J, Alarcão J, Fareleira F, et al. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015;5(5):CD009923.
   Google Scholar
• Buynak R, Rappaport SA, Rod K, et al. Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial. Clin Ther. 2015;37(11):2420–2438.
   PubMed Web of Science ®Google Scholar
• Els C, Jackson TD, Kunyk D, et al. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;10:CD012509.
   PubMed Web of Science ®Google Scholar
• Otto JC, Forstenpointner J, Sachau J, et al. A novel algorithm to identify predictors of treatment response: tapentadol monotherapy or tapentadol/pregabalin combination therapy in chronic low back pain? Front Neurol. 2019;10:979.
   PubMed Web of Science ®Google Scholar
• D'Amato T, Martorelli F, Fenocchio G, et al. Tapentadol vs oxycodone/naloxone in the management of pain after total hip arthroplasty in the fast track setting: an observational study. J Exp Orthop. 2019;6(1):36.
   PubMedGoogle Scholar